Clinical Trial Applications - Approved: Filter, Search, and view applications


Clear
Extended search...

Page 39 of 58, showing 10 Applications out of 576 total, starting on record 381, ending on 390

# Protocol No Study Title Investigator(s) & Site(s) Date Approved

381.

ECCT/26/02/04   RSV IMPACT TRIAL
    A Phase-IIIb individually randomized, placebo-controlled trial on safety of RSVA/B-preF vaccine in pregnant women and efficacy against severe RSV-associated lower respiratory tract infection (LRTI) in infants.   
Principal Investigator(s)
1. Joyce Uchi Nyiro
2. Makobu Kimani
Site(s) in Kenya
1. Kilifi, KEMRI-Centre for Geographic Medicine Research Coast (CGMRC) (Kilifi county)
 
28-05-2026 View

382.

ECCT/25/11/03   RSV IMPACT TRIAL
    A Phase-IIIb individually randomized, placebo-controlled trial on safety of RSVA/B-preF vaccine in pregnant women and efficacy against severe RSV-associated lower respiratory tract infection in infants.   
Principal Investigator(s)
1. Nancy A. Otieno
2. Evans M. Ogoti
Site(s) in Kenya
Kenya Medical Research Institute, Centre for Global Health Research - Siaya (KE1)
 
09-02-2026 View

383.

ECCT/23/03/03   Moderna 1273
    A Phase 2/3, Randomized, Observer-Blind, Placebo‑Controlled Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA‑1273 SARS‑CoV‑2 Vaccine in Healthy Adolescents 12 to <18 Years of Age   
Principal Investigator(s)
1. Prof. Walter Godfrey Jaoko Jaoko
Site(s) in Kenya
1. KAVI Institute of Clinical Reasearch, College of Health science (Nairobi City county)
2. Victoria Biomedical Research Institute (Kisumu county)
3. KEMRI/USAMRD (Kericho county)
4. Kenya Medical Research Institute/USAMRU (Kisumu county)
5. KEMRI CMR-Kar Geno Research Centre (Kisumu county)
6. KEMRI CRDR - Clinical Research Nairobi (Nairobi City county)
7. KEMRI/ CDC (Kisumu county)
8. KEMRI (Kisumu county)
9. KEMRI Centre for Clinical Research Butere County Hospital (Kakamega county)
 
12-05-2023 View

384.

ECCT/24/11/03   REALISE STUDY PROTOCOL
    A Pragmatic Phase III Multi-Centre Clinical Trial to Evaluate the Safety and 1 Effectiveness of a Single Dose of an Albendazole-Ivermectin Coformulation vs 2 Albendazole for Preventive Chemotherapy of Soil-Transmitted Helminth Infections in 3 School-Aged Children   
Principal Investigator(s)
1. Alejandro Javier Krolewiecki
Site(s) in Kenya
Kwale county
 
19-06-2025 View

385.

ECCT/21/11/02   SONIA Trial
    A Pragmatic Randomized Controlled Trial of Standard Care versus Steroids plus Standard Care for Treatment of Pneumonia in Adults Admitted to Kenyan Hospitals       
Principal Investigator(s)
1. Anthony Oliwa Etyang
2. Samuel Owuor Akech
Site(s) in Kenya
1. Kilifi County Hospital (Kilifi county)
2. Mbagathi Sub-county Hospital (Nairobi City county)
3. Busia County Referral Hospital (Busia county)
4. Bungoma County Referral Hospital (Bung\'oma county)
5. Kisumu County Hospital (Kisumu county)
6. Machakos Level 5 Hospital (Machakos county)
7. Mama Lucy Kibaki Hospital (Nairobi City county)
8. Kitale County Referral Hospital (Trans Nzoia county)
9. Kiambu County Hospital (Kiambu county)
10. Kakamega County Hospital (Kakamega county)
 
06-04-2022 View

386.

ECCT/19/06/01   EPI 003
    A prospective study to evaluate the safety, effectiveness and impact of the RTS,S/AS01E vaccine in young children in sub-Saharan Africa.   
Principal Investigator(s)
1. Walter Otieno
Site(s) in Kenya
1. Ahero clinical triasl unit (Kisumu county)
2. KEMI CDC (Siaya county)
 
17-06-2019 View

387.

ECCT/18/11/02   EPI 003
    A prospective study to evaluate the safety, effectiveness and impact of the RTS,S/AS01E vaccine in young children in sub-Saharan Africa.   
Principal Investigator(s)
1. BERNHARDS OGUTU
Site(s) in Kenya
1. • Ahero Clinical Trials Unit (Kisumu county)
2. KEMRI Walter Reed Army Institute of Research (Kisumu county)
3. KEMRI CDC SIAYA (Siaya county)
 
25-03-2019 View

388.

ECCT/09/03/01   REMoxTB
    A randomised placebo – controlled double blind trial comparing two treatment shortening regimens with the standard regimen (two months ethambutol,  isoniazid, rifampicin and pyrazinamide followed by four months isoniazid and rifampicin) namely 1) two months moxifloxacin, isoniazid, rifampicin and  pyrazinamide followed by two months moxifloxacin, isoniazid and rifampicin and 2) two months ethambutol, moxifloxacin, rifampicin and pyrazinamide followed by  two months moxifloxacin and rifampicin for the treatment of adults with pulmonary tuberculosis   
Principal Investigator(s)
1. Evans Inyangala Amukoye
Site(s) in Kenya
Kibera D.O Health Centre
 
01-07-2013 View

389.

ECCT/18/07/06   Hestia 3
    A Randomised, Double-Blind, Parallel-Group, Multicentre, Phase III Study to Evaluate the Effect of Ticagrelor versus Placebo in Reducing the Rate of Vaso-Occlusive Crises in Paediatric Patients with Sickle Cell Disease   
Principal Investigator(s)
1. Prof Jessie Nyokabi Githanga
2. Videlis Nduba
3. Janet N Oyieko
4. Bernards Ragama Ogutu
Site(s) in Kenya
1. Gertrude’s Children’s Hospital (Nairobi City county)
2. Chandaria Health Center Clinical Research Clinic (Nairobi City county)
3. Kenya Medical Research Institute (KEMRI) Kisumu (Kisumu county)
4. KEMRI Kombewa Clinical Research Centre (Nairobi City county)
5. Kondele Children\'s Hospital (Kisumu county)
6. Strathmore University Medical Centre (Nairobi City county)
 
06-10-2018 View

390.

ECCT/16/07/02   A Randomized Trial of Inflienza Vaccine to Reduce Adverse Vascular Events
    A Randomized Trial of Inflienza Vaccine to Reduce Adverse Vascular Events   
Principal Investigator(s)
1. Mark Loeb
Site(s) in Kenya
The Aga Khan University Hospital
 
17-08-2016 View